Ƶ

Promising New Depression Tx; Racially Skewed ADHD Dx; Effective Clozapine Monitoring

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

The FDA gave during a pre-investigational new drug meeting on the phase IIIb clinical program testing their drug ANT-01 as adjunctive therapy for major depression, the company announced.

Is there a genetic reason why more women are ? (Alzheimer's & Dementia)

Compared with other races and ethnicities, white children may be more likely to be both ). (Journal of Learning Disabilities)

A sided with three drug distributors -- AmerisourceBergen, Cardinal Health, and McKesson -- dismissing claims that they contributed to the opioid crisis. (Washington Post)

In a review of listed in Oregon Medicaid directories, researchers found that 59-67% of mental health providers weren't actually seeing Medicaid patients. "If the majority of providers are not actually accessible, it leads to delays and interruptions in care and treatment that people need," said study author Jane M. Zhu, MD, of Oregon Health & Science University, in a statement. (Health Affairs)

A found that if the U.K. applied the revised FDA monitoring criteria for clozapine, it would greatly cut back on drug discontinuation for hematologic reasons. (The Lancet Psychiatry)

Engagement in was low across New York residents in all Medicaid private plans. (JAMA Health Forum)

A was reached in a lawsuit alleging abuse on behalf of an inpatient at Connecticut's Whiting Forensic Hospital, a maximum-security psychiatric hospital. (AP)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.